Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

 

Date of Report (Date of earliest event reported): July 14, 2005

 


 

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware   1-1136   22-079-0350

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification Number)

 

345 Park Avenue

New York, NY, 10154

(Address of Principal Executive Office)

 

Registrant’s telephone number, including area code: (212) 546-4000

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01. Other Events.

 

On July 14, 2005, Bristol-Myers Squibb Company issued a press release announcing that it had signed a definitive agreement for the sale of its U.S. and Canadian Consumer Medicines business and related assets to Novartis AG. Under the agreement, Novartis AG will pay Bristol-Myers Squibb Company $660 million in cash at closing. The transaction is subject to customary regulatory approvals and is expected to close by the end of the third quarter. A copy of the press release is attached to this report as Exhibit 99.1.

 

Item 9.01 Financial Statement and Exhibits

 

  (c) Exhibits

 

  99.1 Press release, dated July 14, 2005


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Bristol-Myers Squibb Company
Dated: July 15, 2005   By:  

/s/ Sandra Leung


    Name:   Sandra Leung
    Title:   Secretary


EXHIBIT INDEX

 

Exhibit No.

 

Description


99.1   Press Release, dated July 14, 2005